))
Trending News US – April 4, 2024
Manage episode 410642750 series 3046075
Content provided by Vynamic. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Vynamic or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://ppacc.player.fm/legal.
In this Trending News US episode, Jen, Mindy, and Ryan discuss recent newsworthy items, including the introduction of rebate credits by CVS to account for more biosimilars entering the market, as well as a recent ruling by a federal appeals court that drugmakers cannot restrict 340B program offerings from community and specialty pharmacies. Finally, we discuss a groundbreaking procedure in which a kidney from a CRISPR gene edited pig was transplanted into a human.
Podcast Tags: healthcare, healthcare news, CVS health, PBMs, biosimilars, 340B, pharmacies, hospitals, providers, xenotransplantation, CRISPR, gene editing
Source Links:
- As Humira biosimilars take over the market, CVS has created a new ploy; the drug “rebate credit”
- Federal appeals court sides with 340B contract pharmacies
- American Hospital Association 340B Factsheet
- Gene edited pig kidney transplanted into a living patient for the first time
- Kidney Disease Statistics for the United States
Panel – Jen Burke, Mindy McGrath, Ryan Hummel
Research & Production – Anna Briccetti, Jen Burke
Recording & Editing – Mike Liberto, Rachel Skonecki
For additional discussion, please contact us at TrendingHealth.com or share a voicemail at 1-888-VYNAMIC.
210 episodes
Share
